Skip to Content

Health

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug

Reuters (CNN) — The U.S. Food and Drug Administration on Wednesday approved Revolution Medicines’ targeted drug for adults with ​metastatic pancreatic cancer who have received prior treatment or ‌cannot receive combination chemotherapy. The drug, branded as Rasonque and also known as daraxonrasib, is a once-daily pill designed to block several forms of the RAS protein,

Continue Reading